An update on adenosine A2A receptors as drug target in Parkinson's Disease

CNS and Neurological Disorders - Drug Targets

Volumn 10, Issue 6, 2011, Pages 659-669

  Vallano, Antoni ^a,b   Fernández Dueñas, Víctor ^b   Pedrós, Consuelo ^a,b   Arnau, Josep María ^a,b   Ciruela, Francisco ^b  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Adenosine A2A; Clinical trial; GPCR oligomerization; Istradefylline; Parkinson's disease; Preladenant; Receptors

Indexed keywords

5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; ADENOSINE; ADENOSINE A2 RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; ANTIPARKINSON AGENT; BROMOCRIPTINE; CABERGOLINE; CARBIDOPA; DOPAMINE; ENTECAPONE; ERGOT ALKALOID; ISTRADEFYLLINE; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; PRELADENANT; RASAGILINE; ROPINIROLE; ROTIGITINE; SELEGILINE; ST 1535; SYN 115; TOLCAPONE; UNCLASSIFIED DRUG; VIPADENANT; ADENOSINE A2 RECEPTOR ANTAGONIST; ADENOSINE A2A RECEPTOR; PURINE DERIVATIVE; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATTENTION; BASAL GANGLION; CENTRAL NERVOUS SYSTEM; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG INDUCED HEADACHE; DRUG TARGETING; DRUG WITHDRAWAL; DYSKINESIA; FATIGUE; GASTROINTESTINAL DISEASE; GENE THERAPY; HALLUCINATION; HUMAN; INSOMNIA; MENTAL DISEASE; MOTOR DYSFUNCTION; NAUSEA; NERVE CELL; NERVE DEGENERATION; NEUROBIOLOGY; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; RECEPTOR AFFINITY; RESPIRATORY TRACT DISEASE; RHINOPHARYNGITIS; STEM CELL TRANSPLANTATION; SYMPTOM; UPPER RESPIRATORY TRACT INFECTION; METABOLISM; METHODOLOGY; MOLECULARLY TARGETED THERAPY; PHYSIOLOGY; REVIEW;

ADENOSINE A2 RECEPTOR ANTAGONISTS; HUMANS; MOLECULAR TARGETED THERAPY; PARKINSON DISEASE; PURINES; PYRIMIDINES; RECEPTOR, ADENOSINE A2A; TRIAZOLES;

EID: 80052852568     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/187152711797247803     Document Type: Article

References (67)

1. Newby, A.C. Adenosine and the concept of retaliatory metabolites. Trends Biochem. Sci., 1984, 9, 42-44
2. Ferre, S.; Ciruela, F.; Quiroz, C.; Lujan, R.; Popoli, P.; Cunha, R.A.; Agnati, L.F.; Fuxe, K.; Woods, A.S.; Lluis, C.; Franco, R. Adenosine receptor heteromers and their integrative role in striatal function. Sci. World J., 2007, 7, 74-85
3. Latini, S.; Pedata, F. Adenosine in the central nervous system: Release mechanisms and extracellular concentrations. J. Neurochem., 2001, 79, 463-484
4. Snyder, S.H. Adenosine as a neuromodulator. Annu. Rev. Neurosci., 1985, 8, 103-124
5. Ferre, S.; Fuxe, K. Adenosine as a volume transmission signal. A feedback detector of neuronal activation. Prog. Brain Res., 2000, 125, 353-361
6. Fredholm, B.B. Purinoceptors in the nervous system. Pharmacol. Toxicol., 1995, 76, 228-239
7. Klyuch, B.P.; Richardson, M.J.; Dale, N.; Wall, M.J. The dynamics of single spike-evoked adenosine release in the cerebellum. J. Physiol., 2011, 589, 283-295
8. Dunwiddie, T.V.; Masino, S.A. The role and regulation of adenosine in the central nervous system. Annu. Rev. Neurosci., 2001, 24, 31-55
9. Ciruela, F.; Casado, V.; Rodrigues, R.J.; Lujan, R.; Burgueno, J.; Canals, M.; Borycz, J.; Rebola, N.; Goldberg, S.R.; Mallol, J.; Cortes, A.; Canela, E.I.; Lopez-Gimenez, J.F.; Milligan, G.; Lluis, C.; Cunha, R.A.; Ferre, S.; Franco, R. Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers. J. Neurosci., 2006, 26, 2080-2087
10. Ciruela, F.; Gomez-Soler, M.; Guidolin, D.; Borroto-Escuela, D.O.; Agnati, L.F.; Fuxe, K.; Fernandez-Duenas, V. Adenosine receptor containing oligomers: their role in the control of dopamine and glutamate neurotransmission in the brain. Biochim. Biophys. Acta, 2011, 1808, 1245-1255
11. Cabello, N.; Gandia, J.; Bertarelli, D.C.; Watanabe, M.; Lluis, C.; Franco, R.; Ferre, S.; Lujan, R.; Ciruela, F. Metabotropic glutamate type 5, dopamine D(2) and adenosine A(2a) receptors form higher-order oligomers in living cells. J. Neurochem., 2009, 109, 1497-1507
12. Hely, M.A.; Morris, J.G.; Reid, W.G.; Trafficante, R. Sydney multicenter study of parkinson's disease: Non-L-dopa-responsive problems dominate at 15 years. Mov. Disord., 2005, 20, 190-199
13. Lang, A.E.; Lozano, A.M. Parkinson's disease. First of two parts. N. Engl. J. Med., 1998, 339, 1044-1053
14. Braak, H.; Del Tredici, K.; Rub, U.; de Vos, R.A.; Jansen Steur, E.N.; Braak, E. Staging of brain pathology related to sporadic parkinson's disease. Neurobiol. Aging, 2003, 24, 197-211
15. Zarow, C.; Lyness, S.A.; Mortimer, J.A.; Chui, H.C. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in alzheimer and parkinson diseases. Arch. Neurol., 2003, 60, 337-341
16. Spillantini, M.G.; Schmidt, M.L.; Lee, V.M.; Trojanowski, J.Q.; Jakes, R.; Goedert, M. Alpha-synuclein in lewy bodies. Nature, 1997, 388, 839-840
17. Reiner, A.; Medina, L.; Haber, S.N. The distribution of dynorphinergic terminals in striatal target regions in comparison to the distribution of substance P-containing and enkephalinergic terminals in monkeys and humans. Neuroscience, 1999, 88, 775-793
18. Steiner, H.; Gerfen, C.R. Role of dynorphin and enkephalin in the regulation of striatal output pathways and behavior. Exp. Brain Res., 1998, 123, 60-76
19. Perreault, M.L.; Hasbi, A.; Alijaniaram, M.; Fan, T.; Varghese, G.; Fletcher, P.J.; Seeman, P.; O'Dowd, B.F.; George, S.R. The dopamine D1-D2 receptor heteromer localizes in dynorphin/enkephalin neurons: Increased high affinity state following amphetamine and in schizophrenia. J. Biol. Chem., 2010, 285, 36625-36634
20. Bornstein, A.M.; Daw, N.D. Multiplicity of control in the basal ganglia: Computational roles of striatal subregions. Curr. Opin. Neurobiol., 2011, 21(3), 374-380
21. Fuxe, K.; Marcellino, D.; Borroto-Escuela, D.O.; Guescini, M.; Fernandez-Duenas, V.; Tanganelli, S.; Rivera, A.; Ciruela, F.; Agnati, L.F. Adenosine-dopamine interactions in the pathophysiology and treatment of CNS disorders. CNS Neurosci. Ther., 2010, 16, e18-e42
22. Cotzias, G.C.; Van Woert, M.H.; Schiffer, L.M. Aromatic amino acids and modification of parkinsonism. N. Engl. J. Med., 1967, 276, 374-379
23. Olanow, C.W. MAO-B inhibitors in parkinson's disease. Adv. Neurol., 1993, 60, 666-671
24. Piccini, P.; Brooks, D.J.; Korpela, K.; Pavese, N.; Karlsson, M.; Gordin, A. The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to sinemet CR in parkinson's disease. J. Neurol. Neurosurg. Psychiatry, 2000, 68, 589-594
25. Olanow, C.W.; Stocchi, F. COMT inhibitors in parkinson's disease: Can they prevent and/or reverse levodopa-induced motor complications? Neurology, 2004, 62, S72-S81
26. Schapira, A.H.; Bezard, E.; Brotchie, J.; Calon, F.; Collingridge, G.L.; Ferger, B.; Hengerer, B.; Hirsch, E.; Jenner, P.; Le Novere, N.; Obeso, J.A.; Schwarzschild, M.A.; Spampinato, U.; Davidai, G. Novel pharmacological targets for the treatment of parkinson's disease. Nat. Rev. Drug Discov., 2006, 5, 845-854
27. Rascol, O.; Brooks, D.J.; Korczyn, A.D.; De Deyn, P.P.; Clarke, C.E.; Lang, A.E. A five-year study of the incidence of dyskinesia in patients with early parkinson's disease who were treated with ropinirole or levodopa. 056 study group. N. Engl. J. Med., 2000, 342, 1484-1491
28. Meyer, A.K.; Maisel, M.; Hermann, A.; Stirl, K.; Storch, A. Restorative approaches in parkinson's disease: Which cell type wins the race? J. Neurol. Sci., 2010, 289, 93-103
29. Hermann, A.; Gerlach, M.; Schwarz, J.; Storch, A. Neurorestoration in parkinson's disease by cell replacement and endogenous regeneration. Expert Opin. Biol. Ther., 2004, 4, 131-143
30. Popoli, P.; Pezzola, A.; Torvinen, M.; Reggio, R.; Pintor, A.; Scarchilli, L.; Fuxe, K.; Ferre, S. The selective mGlu(5) receptor agonist CHPG inhibits quinpirole-induced turning in 6- hydroxydopamine-lesioned rats and modulates the binding characteristics of dopamine D(2) receptors in the rat striatum: interactions with adenosine A(2a) receptors. Neuropsychopharmacology, 2001, 25, 505-513
31. Carriba, P.; Navarro, G.; Ciruela, F.; Ferre, S.; Casado, V.; Agnati, L.; Cortes, A.; Mallol, J.; Fuxe, K.; Canela, E.I.; Lluis, C.; Franco, R. Detection of heteromerization of more than two proteins by sequential BRET-FRET. Nat. Methods, 2008, 5, 727-733
32. Ferre, S.; Quiroz, C.; Woods, A.S.; Cunha, R.; Popoli, P.; Ciruela, F.; Lluis, C.; Franco, R.; Azdad, K.; Schiffmann, S.N. An update on adenosine A2A-dopamine D2 receptor interactions: Implications for the function of G protein-coupled receptors. Curr. Pharm. Des., 2008, 14, 1468-1474
33. Schwarzschild, M.A.; Agnati, L.; Fuxe, K.; Chen, J.F.; Morelli, M. Targeting adenosine A2A receptors in parkinson's disease. Trends Neurosci., 2006, 29, 647-654
34. Jenner, P. Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of parkinson's disease. Expert Opin. Investig. Drugs, 2005, 14, 729-738
35. LeWitt, P.A.; Guttman, M.; Tetrud, J.W.; Tuite, P.J.; Mori, A.; Chaikin, P.; Sussman, N.M.; 6002-US-005 Study Group. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces off time in parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005). Ann. Neurol., 2008, 63, 295-302
36. Antonelli, T.; Fuxe, K.; Agnati, L.; Mazzoni, E.; Tanganelli, S.; Tomasini, M.C.; Ferraro, L. Experimental studies and theoretical aspects on A2A/D2 receptor interactions in a model of parkinson's disease. relevance for L-dopa induced dyskinesias. J. Neurol. Sci., 2006, 248, 16-22
37. Calon, F.; Dridi, M.; Hornykiewicz, O.; Bedard, P.J.; Rajput, A.H.; Di Paolo, T. Increased adenosine A2A receptors in the brain of parkinson's disease patients with dyskinesias. Brain, 2004, 127, 1075-1084
38. Bibbiani, F.; Oh, J.D.; Petzer, J.P.; Castagnoli, N., Jr.; Chen, J.F.; Schwarzschild, M.A.; Chase, T.N. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of parkinson's disease. Exp. Neurol., 2003, 184, 285-294
39. Frau, L.; Borsini, F.; Wardas, J.; Khairnar, A.S.; Schintu, N.; Morelli, M. Neuroprotective and anti-inflammatory effects of the adenosine A(2A) receptor antagonist ST1535 in a MPTP mouse model of parkinson's disease. Synapse, 2011, 65, 181-188
40. Ramlackhansingh, A.F.; Bose, S.K.; Ahmed, I.; Turkheimer, F.E.; Pavese, N.; Brooks, D.J. Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with parkinson disease. Neurology, 2011, 76, 1811-1816
41. Chen, J.F.; Huang, Z.; Ma, J.; Zhu, J.; Moratalla, R.; Standaert, D.; Moskowitz, M.A.; Fink, J.S.; Schwarzschild, M.A. A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J. Neurosci., 1999, 19, 9192-9200
42. Dall'Igna, O.P.; Porciuncula, L.O.; Souza, D.O.; Cunha, R.A.; Lara, D.R. Neuroprotection by caffeine and adenosine A2A receptor blockade of beta-amyloid neurotoxicity. Br. J. Pharmacol., 2003, 138, 1207-1209
43. Melani, A.; Pantoni, L.; Bordoni, F.; Gianfriddo, M.; Bianchi, L.; Vannucchi, M.G.; Bertorelli, R.; Monopoli, A.; Pedata, F. The selective A2A receptor antagonist SCH 58261 reduces striatal transmitter outflow, turning behavior and ischemic brain damage induced by permanent focal ischemia in the rat. Brain Res., 2003, 959, 243-250
44. Fink, J.S.; Kalda, A.; Ryu, H.; Stack, E.C.; Schwarzschild, M.A.; Chen, J.F.; Ferrante, R.J. Genetic and pharmacological inactivation of the adenosine A2A receptor attenuates 3-nitropropionic acidinduced striatal damage. J. Neurochem., 2004, 88, 538-544
45. Carta, A.R.; Kachroo, A.; Schintu, N.; Xu, K.; Schwarzschild, M.A.; Wardas, J.; Morelli, M. Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of parkinson's disease. J. Neurochem., 2009, 111, 1478-1489
46. Fox, S.H.; Brotchie, J.M.; Lang, A.E. Non-dopaminergic treatments in development for parkinson's disease. Lancet Neurol., 2008, 7, 927-938
47. Morelli, M.; Carta, A.R.; Jenner, P. Adenosine A2A receptors and parkinson's disease. Handb. Exp. Pharmacol., 2009, 193, 589-615
48. Simola, N.; Morelli, M.; Pinna, A. Adenosine A2A receptor antagonists and parkinson's disease: State of the art and future directions. Curr. Pharm. Des., 2008, 14, 1475-1489
49. Jenner, P.; Mori, A.; Hauser, R.; Morelli, M.; Fredholm, B.B.; Chen, J.F. Adenosine, adenosine A 2A antagonists, and parkinson's disease. Parkinsonism Relat. Disord., 2009, 15, 406-413
50. Cieslak, M.; Komoszynski, M.; Wojtczak, A. Adenosine A(2A) receptors in parkinson's disease treatment. Purinergic Signal., 2008, 4, 305-312
51. Pinna, A. Novel investigational adenosine A2A receptor antagonists for parkinson's disease. Expert Opin. Investig. Drugs, 2009, 18, 1619-1631
52. Muller, T. New small molecules for the treatment of parkinson's disease. Expert Opin. Investig. Drugs, 2010, 19, 1077-1086
53. Lundblad, M.; Vaudano, E.; Cenci, M.A. Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia. J. Neurochem., 2003, 84, 1398-1410
54. Pierri, M.; Vaudano, E.; Sager, T.; Englund, U. KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse. Neuropharmacology, 2005, 48, 517-524
55. Koga, K.; Kurokawa, M.; Ochi, M.; Nakamura, J.; Kuwana, Y. Adenosine A(2A) receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemiparkinsonian rats. Eur. J. Pharmacol., 2000, 408, 249-255
56. Kanda, T.; Jackson, M.J.; Smith, L.A.; Pearce, R.K.; Nakamura, J.; Kase, H.; Kuwana, Y.; Jenner, P. Adenosine A2A antagonist: A novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann. Neurol., 1998, 43, 507-513
57. Kanda, T.; Jackson, M.J.; Smith, L.A.; Pearce, R.K.; Nakamura, J.; Kase, H.; Kuwana, Y.; Jenner, P. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp. Neurol., 2000, 162, 321-327
58. Grondin, R.; Bedard, P.J.; Hadj Tahar, A.; Gregoire, L.; Mori, A.; Kase, H. Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys. Neurology, 1999, 52, 1673-1677
59. Hauser, R.A.; Schwarzschild, M.A. Adenosine A2A receptor antagonists for parkinson's disease: Rationale, therapeutic potential and clinical experience. Drugs Aging, 2005, 22, 471-482
60. Knebel, W.; Rao, N.; Uchimura, T.; Mori, A.; Fisher, J.; Gastonguay, M.R.; Chaikin, P. Population pharmacokinetic analysis of istradefylline in healthy subjects and in patients with parkinson's disease. J. Clin. Pharmacol., 2011, 51, 40-52
61. Bara-Jimenez, W.; Sherzai, A.; Dimitrova, T.; Favit, A.; Bibbiani, F.; Gillespie, M.; Morris, M.J.; Mouradian, M.M.; Chase, T.N. Adenosine A(2A) receptor antagonist treatment of parkinson's disease. Neurology, 2003, 61, 293-296
62. Hauser, R.A.; Hubble, J.P.; Truong, D.D.; Istradefylline US-001 Study Group. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology, 2003, 61, 297-303
63. Hauser, R.A.; Shulman, L.M.; Trugman, J.M.; Roberts, J.W.; Mori, A.; Ballerini, R.; Sussman, N.M.; Istradefylline 6002-US-013 Study Group. Study of istradefylline in patients with parkinson's disease on levodopa with motor fluctuations. Mov. Disord., 2008, 23, 2177-2185
64. Stacy, M.; Silver, D.; Mendis, T.; Sutton, J.; Mori, A.; Chaikin, P.; Sussman, N.M. A 12-week, placebo-controlled study (6002-US- 006) of istradefylline in parkinson disease. Neurology, 2008, 70, 2233-2240
65. Mizuno, Y.; Hasegawa, K.; Kondo, T.; Kuno, S.; Yamamoto, M.; Japanese Istradefylline Study Group. Clinical efficacy of istradefylline (KW-6002) in parkinson's disease: A randomized, controlled study. Mov. Disord., 2010, 25, 1437-1443
66. Fernandez, H.H.; Greeley, D.R.; Zweig, R.M.; Wojcieszek, J.; Mori, A.; Sussman, N.M.; 6002-US-051 Study Group. Istradefylline as monotherapy for parkinson disease: Results of the 6002-US-051 trial. Parkinsonism Relat. Disord., 2010, 16, 16-20
67. Hauser, R.A.; Cantillon, M.; Pourcher, E.; Micheli, F.; Mok, V.; Onofrj, M.; Huyck, S.; Wolski, K. Preladenant in patients with parkinson's disease and motor fluctuations: A phase 2, double- blind, randomised trial. Lancet Neurol., 2011, 10, 221-229